Please use this identifier to cite or link to this item: https://hdl.handle.net/2440/130001
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: Analysis of blood mature BDNF and proBDNF in mood disorders with specific ELISA assays
Author: Lin, L.
Fu, X.Y.
Zhou, X.F.
Liu, D.
Bobrovskaya, L.
Zhou, L.
Citation: Journal of Psychiatric Research, 2021; 133:166-173
Publisher: Elsevier
Issue Date: 2021
ISSN: 0022-3956
1879-1379
Statement of
Responsibility: 
Liying Lin, Xi-yue Fu, Xin-Fu Zhou, Dennis Liu, Larisa BobrovskayabLi Zhou
Abstract: Previous studies showed that blood BDNF levels in mood disorders were reduced. However, little is known about the changes of BDNF and its precursor proBDNF in lymphocytes. In addition, earlier studies using commercial ELISA kits cannot distinguish mature BDNF from proBDNF. We aimed to investigate the change of mBDNF and proBDNF levels in the peripheral blood and their diagnostic value in the mood disorders using a specific Enzyme-Linked Immunosorbent Assay (ELISA). Serum mBDNF levels were significantly decreased in major depressive disorder (MDD) (n = 90) and bipolar disorder (BD) (n = 15) groups (P < 0.0001), whereas there was no significant change in suicidal group (n = 14) compared to the control group (n = 96). In the subgroups of MDD, the serum mBDNF level in MDD patients with severe symptoms was significantly lower than that with moderate symptoms (P < 0.05). The serum mBDNF levels in antidepressant-free patients were significantly lower than in antidepressant-treated patients (P < 0.01). Serum mBDNF yielded good diagnostic effectiveness for MDD and BD with sensitivity and specificity around 80–83%. The levels of mBDNF, proBDNF and its receptor sortilin were upregulated in lymphocytes of MDD patients relative to control subjects. Specific ELISA assays for mature BDNF confirmed the reduction of serum mBDNF level in MDD and BD. The measurement of mBDNF level could be a potential diagnostic marker with a cut-off point at 12.4 ng/ml. Upregulations of proBDNF and mBDNF in lymphocytes of MDD patients might be considered as novel pathological biomarkers for MDD.
Keywords: Mood disorders; MDD; mBDNF; proBDNF; ELISA; Lymphocytes
Rights: © 2020 Elsevier Ltd. All rights reserved.
DOI: 10.1016/j.jpsychires.2020.12.021
Grant ID: NHMRC
Appears in Collections:Aurora harvest 4
Psychiatry publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.